Form 4: Scholar Rock CEO David Hallal Acquires Shares Through Restricted Stock Units

CEO David Hallal reports acquisition of Scholar Rock Holding Corp shares through restricted stock units and performance-based restricted stock units.

Summary

• On April 27, 2025, David Hallal, CEO of Scholar Rock Holding Corp, acquired 250,000 shares of common stock through restricted stock units (RSUs).
• These RSUs vest in four annual installments starting April 15, 2026, contingent upon continued service with the Issuer.
• Hallal also acquired 1,250,000 shares through performance-based RSUs (PSUs), bringing his total holdings to 1,804,095 shares.
• The PSUs vest based on a combination of performance targets related to the Issuer's stock price and time-based vesting over four years.
• Any PSUs unvested by April 27, 2029, will be forfeited.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management interests with shareholders. The vesting conditions incentivize performance.

Positives

• The acquisition of shares by the CEO demonstrates confidence in the company's future performance.
• The vesting conditions tied to performance may incentivize the CEO to drive company growth and increase shareholder value.

Risks

• The value of the RSUs and PSUs is contingent upon the CEO's continued service with the company.
• The performance-based RSUs are subject to the company's stock price achieving certain targets, which may not be met.

Future Outlook

The vesting of the RSUs and PSUs is contingent upon continued service and, in the case of PSUs, the achievement of certain performance targets related to the company's stock price.

Industry Context

This type of equity compensation is common in the biotech industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and PSUs, are standard practice among publicly traded biotech companies like Amgen, Biogen, and Gilead Sciences.
• The specific vesting schedules and performance targets vary depending on the company's size, stage of development, and strategic goals.
• Generally, performance-based equity awards are designed to incentivize specific milestones, such as clinical trial successes or regulatory approvals, which drive shareholder value.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of shares as a positive sign, indicating confidence in the company's future prospects.
• Employees may be motivated by the CEO's commitment to the company and the potential for increased shareholder value.
• The vesting conditions tied to performance may incentivize the CEO to drive company growth and increase shareholder value, benefiting all stakeholders.

Key Dates

Keywords

Scholar Rock, David Hallal, CEO, Form 4, Beneficial Ownership, Restricted Stock Units, Performance Stock Units, SRRK